Unnati Pharmax

Erlocip 100mg Tablets
Composition: Erlotinib 100mg
International Trade Name: Tarceva®

Erlocip 100mg is a high-quality Erlotinib 100mg Tablet, a therapeutic equivalent of the internationally recognized epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed under the brand name Tarceva®. Manufactured in WHO-GMP certified facilities, Erlocip Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in EGFR-expressing non-small cell lung cancer (NSCLC) and pancreatic cancer.

Erlotinib selectively inhibits the EGFR tyrosine kinase, blocking downstream signaling pathways responsible for tumor cell proliferation, survival, and metastasis. This targeted mechanism enables Erlocip 100mg Tablets to reduce tumor growth while minimizing systemic toxicity.

Erlocip 100mg Tablets are primarily indicated for the treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR-activating mutations and for the management of advanced pancreatic cancer in combination with gemcitabine.

Erlocip 100mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology treatment centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Celofos 1000mg Injection
Composition: Ifosfamide 1000mg
International Trade Name: Ifex®

Celofos 1000mg is a high-quality Ifosfamide 1000mg Injection, a biosimilar equivalent of the internationally recognized alkylating anticancer agent marketed under the brand name Ifex®. Manufactured in WHO-GMP certified facilities, Celofos Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Ifosfamide is an alkylating agent that disrupts DNA replication and RNA transcription in rapidly dividing cancer cells, leading to cell death. This targeted cytotoxic activity enables Celofos 1000mg Injection to treat a wide range of solid tumors, including sarcomas, lymphomas, and testicular cancer, either as monotherapy or in combination with other chemotherapeutic agents.

Celofos 1000mg Injection is primarily indicated for the treatment of various malignant neoplasms in adult and pediatric patients, depending on clinical protocols and disease type.

Celofos 1000mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Erlocip 150mg Tablets
Composition: Erlotinib 150mg
International Trade Name: Tarceva®

Erlocip 150mg is a high-quality Erlotinib 150mg Tablet, a biosimilar equivalent of the internationally recognized epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed under the brand name Tarceva®. Manufactured in WHO-GMP certified facilities, Erlocip Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC) and pancreatic cancer.

Erlotinib selectively inhibits the tyrosine kinase activity of the EGFR, blocking downstream signaling pathways involved in tumor cell proliferation, survival, and angiogenesis. This mechanism enables Erlocip 150mg Tablets to effectively control tumor growth in patients with EGFR mutation-positive NSCLC or locally advanced/metastatic pancreatic cancer.

Erlocip 150mg Tablets are primarily indicated for the treatment of adult patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and for the treatment of pancreatic cancer in combination with gemcitabine.

Erlocip 150mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dacilon 0.5mg Injection
Composition: Dactinomycin 0.5mg
International Trade Name: Cosmegen®

Dacilon 0.5mg is a high-quality Dactinomycin 0.5mg Injection, a biosimilar equivalent of the internationally recognized cytotoxic antibiotic marketed under the brand name Cosmegen®. Manufactured in WHO-GMP certified facilities, Dacilon Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Dactinomycin is a potent antineoplastic agent that intercalates into DNA, inhibiting RNA synthesis and thereby preventing the replication of rapidly dividing cancer cells. This targeted cytotoxic activity enables Dacilon 0.5mg Injection to treat a variety of malignancies, including Wilms’ tumor, rhabdomyosarcoma, Ewing’s sarcoma, and other solid tumors.

Dacilon 0.5mg Injection is primarily indicated for the treatment of pediatric and adult patients with cancers sensitive to Dactinomycin, either as monotherapy or as part of combination chemotherapy regimens, depending on clinical protocols.

Dacilon 0.5mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Hodpro 50mg Capsules
Composition: Procarbazine 50mg
International Trade Name: Matulane and Natulan

Hodpro 50mg is a high-quality Procarbazine 50mg capsule, an effective chemotherapeutic agent supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs. Manufactured in WHO-GMP certified facilities, Hodpro is designed for consistent efficacy and safety in cancer therapy.
Procarbazine is an alkylating agent that works by interfering with DNA, RNA, and protein synthesis in cancer cells, inhibiting their growth and proliferation. Hodpro 50mg Capsules are primarily indicated for the treatment of Hodgkin’s lymphoma and certain other cancers as part of combination chemotherapy regimens.
Hodpro 50mg Capsules are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Pamorelin 3.75mg Injection
Composition: Triptorelin 3.75mg
International Trade Name: Decapeptyl®

Pamorelin 3.75mg is a high-quality Triptorelin 3.75mg Injection, a therapeutic equivalent of the internationally recognized luteinizing hormone-releasing hormone (LHRH) agonist marketed under the brand name Decapeptyl®. Manufactured in WHO-GMP certified facilities, Pamorelin Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and endocrinology treatment programs.

Triptorelin is a synthetic decapeptide LHRH agonist that suppresses the production of sex hormones (testosterone and estrogen) through reversible downregulation of pituitary gonadotropins. This targeted hormone modulation helps manage hormone-dependent conditions, including advanced prostate cancer, breast cancer, endometriosis, and other gynecological disorders, as well as in assisted reproduction protocols.

Pamorelin 3.75mg Injection is primarily indicated for the treatment of advanced prostate cancer in men, hormone-dependent breast cancer in pre- and peri-menopausal women, and endometriosis in women. It is suitable for medical castration or hormone suppression therapy under specialist supervision.

Pamorelin 3.75mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology and gynecology treatment centers, tertiary care hospitals, government healthcare programs, and international pharmaceutical distributors.

Mycept S 360 Tablets
Composition: Mycophenolic Acid Delayed-Release 360mg
International Trade Name: Myfortic®

Mycept S 360 is a high-quality Mycophenolic Acid Delayed-Release 360mg tablet, designed to support immunosuppressive therapy in transplant recipients. Manufactured in WHO-GMP certified facilities, Mycept S 360 is supplied by trusted pharmaceutical exporters from India to support advanced global transplant care programs.

Mycophenolic Acid is a potent inhibitor of inosine monophosphate dehydrogenase, selectively suppressing lymphocyte proliferation and immune response. Mycept S 360 Tablets are primarily indicated for the prevention of organ rejection in kidney, liver, and heart transplant patients, as part of combination immunosuppressive therapy.

Mycept S 360 Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for tertiary care hospitals, transplant centers, government health programs, and international pharmaceutical distributors.

Cresp 100 µg Injection
Composition: Darbepoetin Alfa 100 µg
Dosage Form: Injectable Solution

Cresp 100 µg Injection is a high-quality Darbepoetin Alfa formulation, a biosimilar equivalent of the internationally recognized erythropoiesis-stimulating agent used to treat anemia. Manufactured in WHO-GMP certified facilities, Cresp Injection is supplied by trusted pharmaceutical exporters from India to support global hematology and nephrology treatment programs.

Darbepoetin Alfa is a long-acting erythropoiesis-stimulating protein that promotes red blood cell production by stimulating erythroid progenitor cells in the bone marrow. Cresp 100 µg Injection is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and other conditions requiring erythropoietic support.

 

Cresp Darbepoetin 100 µg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, dialysis centers, oncology units, government health programs, and international pharmaceutical distributors.

Celostatin 100mg Injection
Composition: Octreotide Injection 100mg
International Trade Name: Sandostatin®

Celostatin 100mg is a high-quality Octreotide 100mg Injection, a biosimilar equivalent of the internationally recognized somatostatin analog marketed under the brand name Sandostatin®. Manufactured in WHO-GMP certified facilities, Celostatin Injection is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs, particularly in endocrine disorders and neuroendocrine tumors.

Octreotide is a synthetic octapeptide that mimics natural somatostatin, inhibiting the secretion of several hormones, including growth hormone, insulin, and glucagon. Celostatin 100mg Injection is primarily indicated for the treatment of acromegaly, carcinoid tumors, VIPomas, and other conditions involving hormone-secreting tumors, providing effective symptom control and hormone regulation.

Celostatin 100mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, specialized endocrine centers, government health programs, and international pharmaceutical distributors.

Celplat 10mg Injection
Composition: Cisplatin 10mg
International Trade Name: Platinol®

Celplat 10mg is a high-quality Cisplatin 10mg Injection, a biosimilar equivalent of the internationally recognized platinum-based chemotherapeutic agent marketed under the brand name Platinol®. Manufactured in WHO-GMP certified facilities, Celplat Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Cisplatin is a platinum-containing cytotoxic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, and ultimately inducing apoptosis in rapidly dividing cancer cells. This mechanism enables Celplat 10mg Injection to effectively treat a variety of solid tumors, including testicular, ovarian, bladder, lung, and head and neck cancers.

Celplat 10mg Injection is primarily indicated for the treatment of adult and pediatric patients with malignancies sensitive to Cisplatin, either as monotherapy or in combination with other chemotherapeutic agents according to clinical protocols.

Celplat 10mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Rapamycin 1 mg Tablet
Composition: Sirolimus 1 mg
International Trade Name: Rapamune®

Rapamycin 1 mg Tablet is a high-quality Sirolimus formulation, a biosimilar equivalent of the internationally recognized mTOR inhibitor marketed under the brand name Rapamune®. Manufactured in WHO-GMP certified facilities, Rapamycin Tablets are supplied by trusted pharmaceutical exporters from India to support global immunosuppressive therapy programs.

Sirolimus is an immunosuppressive agent that inhibits the mammalian target of rapamycin (mTOR), preventing T-cell proliferation and reducing the risk of organ transplant rejection. Rapamycin 1 mg Tablet is primarily indicated for the prevention of organ rejection in kidney transplant recipients and may also be used in select off-label conditions requiring immunosuppressive therapy.

Rapamycin Sirolimus 1 mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, transplant centers, government health programs, and international pharmaceutical distributors.

Irinotel 100 mg Injection
Composition: Irinotecan 100 mg
Dosage Form: Injectable Solution
International Trade Name: Camptosar®

Irinotel 100 mg Injection is a high-quality Irinotecan formulation, a biosimilar equivalent of the internationally recognized topoisomerase I inhibitor marketed under the brand name Camptosar®. Manufactured in WHO-GMP certified facilities, Irinotel Injection is supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly in colorectal and other solid tumors.

Irinotecan is a chemotherapeutic agent that inhibits topoisomerase I, preventing DNA replication and transcription in cancer cells, ultimately leading to cell death. Irinotel 100 mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, either as monotherapy or in combination with other chemotherapeutic agents.

Irinotel Irinotecan 100 mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Phoxelon 1000mg Injection
Composition: Cyclophosphamide 1000mg
International Trade Name: Cytoxan®

Phoxelon 1000mg is a high-quality Cyclophosphamide 1000mg Injection, a therapeutic equivalent of the internationally recognized alkylating agent marketed under the brand name Cytoxan®. Manufactured in WHO-GMP certified facilities, Phoxelon Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Cyclophosphamide is an alkylating agent that interferes with DNA replication and transcription, leading to the death of rapidly dividing cancer cells. Phoxelon 1000mg Injection is effective in controlling a wide range of malignancies and is a cornerstone therapy in many chemotherapeutic regimens.

Phoxelon 1000mg Injection is primarily indicated for the treatment of breast cancer, lymphomas, leukemias, ovarian cancer, and other solid tumors and hematologic malignancies. It can be used as monotherapy or as part of combination chemotherapy protocols under specialist supervision.

Phoxelon 1000mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Herduo 250mg Tablets
Composition: Lapatinib 250mg
International Trade Name: Tykerb®

Herduo 250mg is a high-quality Lapatinib 250mg Tablet, a biosimilar equivalent of the internationally recognized dual tyrosine kinase inhibitor marketed under the brand name Tykerb®. Manufactured in WHO-GMP certified facilities, Herduo Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast cancer.

Lapatinib is an oral targeted therapy that inhibits the intracellular tyrosine kinase domains of both HER2 (ErbB2) and EGFR (ErbB1), blocking downstream signaling pathways responsible for tumor cell proliferation and survival. This mechanism enables Herduo 250mg Tablets to effectively control tumor growth in patients with HER2-positive breast cancer, including cases resistant to trastuzumab therapy.

Herduo 250mg Tablets are primarily indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, either as monotherapy or in combination with capecitabine, depending on prior treatment history.

Herduo 250mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Vorizole 200 mg Tablet / Injection
Composition: Voriconazole 200 mg
International Trade Name: Vfend®

Vorizole 200 mg is a high-quality Voriconazole formulation, a biosimilar equivalent of the internationally recognized triazole antifungal agent marketed under the brand name Vfend®. Manufactured in WHO-GMP certified facilities, Vorizole is supplied by trusted pharmaceutical exporters from India to support global antifungal treatment programs, particularly in the management of invasive fungal infections.

Voriconazole is a broad-spectrum antifungal that inhibits fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane formation. Vorizole 200 mg is primarily indicated for the treatment of invasive aspergillosis, candidemia in non-neutropenic patients, serious fungal infections caused by Scedosporium and Fusarium species, and other severe systemic mycoses.

Vorizole Voriconazole 200 mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, infectious disease centers, government health programs, and international pharmaceutical distributors.

Celplat 50mg Injection
Composition: Cisplatin 50mg
International Trade Name: Platinol®

Celplat 50mg is a high-quality Cisplatin 50mg Injection, a therapeutic equivalent of the internationally recognized platinum-based chemotherapeutic agent marketed under the brand name Platinol®. Manufactured in WHO-GMP certified facilities, Celplat Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Cisplatin is a platinum coordination complex that forms DNA cross-links, inhibiting DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells. Celplat 50mg Injection provides targeted cytotoxicity against malignant cells, making it an essential therapy in the management of various solid tumors.

Celplat 50mg Injection is primarily indicated for the treatment of testicular, ovarian, bladder, lung, cervical, and head and neck cancers, as well as other malignancies where platinum-based chemotherapy is recommended. It can be used as monotherapy or in combination chemotherapy regimens under specialist supervision.

Celplat 50mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

5 Flucel 250mg Injection
Composition: Fluorouracil 250mg
International Trade Name: Adrucil® / Efudex®

5 Flucel 250mg is a high-quality Fluorouracil 250mg Injection, a therapeutic equivalent of the internationally recognized antimetabolite marketed under the brand names Adrucil® and Efudex®. Manufactured in WHO-GMP certified facilities, 5 Flucel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis and preventing proliferation of rapidly dividing cancer cells. 5 Flucel 250mg Injection provides targeted cytotoxic activity in malignant tissues, making it a key therapy in multiple solid tumors.

5 Flucel 250mg Injection is primarily indicated for the treatment of colorectal cancer, breast cancer, gastric cancer, pancreatic cancer, and other malignancies where fluorouracil-based chemotherapy is recommended. It can be administered as monotherapy or in combination with other chemotherapeutic agents under specialist supervision.

5 Flucel 250mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Cytodrox 500mg Capsule / Tablet
Composition: Hydroxyurea 500mg
International Trade Name: Droxia®

Cytodrox 500mg is a high-quality Hydroxyurea 500mg formulation, a therapeutic equivalent of the internationally recognized antineoplastic agent marketed under the brand name Droxia®. Manufactured in WHO-GMP certified facilities, Cytodrox is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in myeloproliferative disorders.

Hydroxyurea is an antimetabolite that inhibits ribonucleotide reductase, reducing DNA synthesis and slowing the proliferation of abnormal hematopoietic cells. Cytodrox 500mg helps in controlling elevated blood cell counts, reducing the risk of thrombotic events, and managing complications associated with conditions such as chronic myeloid leukemia, polycythemia vera, and sickle cell anemia.

Cytodrox 500mg is primarily indicated for the treatment of myeloproliferative disorders, chronic myeloid leukemia, and sickle cell anemia, either as monotherapy or as part of a combination regimen under specialist supervision.

Cytodrox 500mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospital oncology units, tertiary care centers, government healthcare programs, and international pharmaceutical distributors.

Grafkid 1mg Capsules
Composition: Tacrolimus 1mg
International Trade Name: Advagraf®

Grafkid 1mg is a high-quality Tacrolimus 1mg capsule, a prolonged-release formulation equivalent to the internationally recognized product marketed under the brand name Advagraf®. Manufactured in WHO-GMP certified facilities, Grafkid is supplied by trusted pharmaceutical exporters from India to support advanced global transplant and immunosuppressive therapy programs.

Tacrolimus is a potent calcineurin inhibitor that suppresses the immune response, reducing the risk of organ rejection in transplant recipients. Grafkid 1mg is primarily indicated for the prevention of kidney, liver, and heart transplant rejection and for the long-term management of patients requiring immunosuppression.

Grafkid 1mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for tertiary care hospitals, transplant centers, government health programs, and international pharmaceutical distributors.

Azadine 100mg Injection
Composition: Azacitidine for Injection 100mg
International Trade Name: Vidaza®

Azadine 100mg is a high-quality Azacitidine 100mg Injection, a biosimilar equivalent of the internationally recognized hypomethylating agent marketed under the brand name Vidaza®. Manufactured in WHO-GMP certified facilities, Azadine Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in hematological malignancies.

Azacitidine is a nucleoside analog of cytidine that incorporates into DNA and RNA, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells. This mechanism enables Azadine 100mg Injection to restore normal gene function and inhibit the proliferation of malignant cells in conditions such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML).

Azadine 100mg Injection is primarily indicated for the treatment of adult patients with myelodysplastic syndromes, including those with intermediate-1, intermediate-2, or high-risk disease categories, as well as selected patients with acute myeloid leukemia.

Azadine 100mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bleocel 15mg Injection
Composition: Bleomycin 15mg
International Trade Name: Blenoxane®

Bleocel 15mg is a high-quality Bleomycin 15mg Injection, a therapeutic equivalent of the internationally recognized cytotoxic antibiotic marketed under the brand name Blenoxane®. Manufactured in WHO-GMP certified facilities, Bleocel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Bleomycin is a glycopeptide antibiotic that binds to DNA, causing strand breaks and inhibiting DNA synthesis, which leads to apoptosis in rapidly dividing cancer cells. Bleocel 15mg Injection provides effective antineoplastic activity with a targeted mechanism, making it suitable for a wide range of malignancies.

Bleocel 15mg Injection is primarily indicated for the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular cancer, squamous cell carcinomas, and other malignancies where bleomycin therapy is recommended. It can be used as monotherapy or in combination chemotherapy protocols under specialist supervision.

Bleocel 15mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Eleftha 440mg Injection
Composition: Trastuzumab 440mg Injection
International Trade Name: Herceptin®

Eleftha 440mg is a high-quality Trastuzumab 440mg Injection, a biosimilar equivalent of the internationally recognized HER2-targeted monoclonal antibody marketed under the brand name Herceptin®. Manufactured in WHO-GMP certified facilities, Eleftha Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast and gastric cancers.

Trastuzumab is a humanized monoclonal antibody that specifically binds to the HER2 receptor, inhibiting proliferation of HER2-overexpressing cancer cells and enhancing immune-mediated cytotoxicity. Eleftha 440mg Injection provides targeted therapy, improving clinical outcomes while minimizing systemic toxicity.

Eleftha 440mg Injection is primarily indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. It is suitable for patients who are naïve to HER2-directed therapy or in combination with chemotherapy.

Eleftha 440mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

 

Mabtas 500 RA Injection
Composition: Rituximab 500mg/50ml
International Trade Name: Rituxan®

Mabtas 500 RA is a high-quality Rituximab 500mg Injection, a biosimilar equivalent of the internationally recognized anti-CD20 monoclonal antibody marketed under the brand name Rituxan®. Manufactured in WHO-GMP certified facilities, Mabtas Injection is supplied by trusted pharmaceutical exporters from India to support advanced global immunology and oncology treatment programs.

Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 antigen expressed on B-lymphocytes, enabling selective depletion of abnormal B-cells while sparing other immune cells. This targeted mechanism makes Mabtas 500 RA Injection effective in the management of B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and autoimmune conditions such as rheumatoid arthritis.

Mabtas 500 RA Injection is primarily indicated for the treatment of adult patients with CD20-positive B-cell malignancies and patients with moderate-to-severe active rheumatoid arthritis who have had an inadequate response to other disease-modifying therapies.

Mabtas 500 RA Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospital infusion centers, tertiary care hospitals, government healthcare programs, and international pharmaceutical distributors.

 

Amferro 50mg Injection
Composition: Ferric Carboxymaltose 50mg
International Trade Name: Injectafer®

Amferro 50mg is a high-quality Ferric Carboxymaltose 50mg Injection, a reliable intravenous iron formulation equivalent to the internationally recognized product marketed under the brand name Injectafer®. Manufactured in WHO-GMP certified facilities, Amferro is supplied by trusted pharmaceutical exporters from India to support advanced global anemia management programs.

Ferric Carboxymaltose is a stable iron complex that allows for rapid and efficient replenishment of iron stores, improving hemoglobin levels and correcting iron deficiency. Amferro 50mg Injection is primarily indicated for the treatment of iron deficiency anemia in adults who are intolerant to oral iron therapy or require rapid correction of iron levels.

Amferro 50mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, infusion centers, government health programs, and international pharmaceutical distributors.

Tigi 50mg Injection
Composition: Tigecycline Injection 50mg
International Trade Name: Tygacil®

Tigi 50mg is a high-quality Tigecycline 50mg Injection, a broad-spectrum glycylcycline antibiotic, equivalent to the internationally recognized product marketed under the brand name Tygacil®. Manufactured in WHO-GMP certified facilities, Tigi Injection is supplied by trusted pharmaceutical exporters from India to support advanced global antimicrobial treatment programs.

Tigecycline is a potent antibiotic structurally related to tetracyclines, with activity against a wide range of Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. Tigi 50mg Injection is primarily indicated for complicated skin and soft tissue infections, intra-abdominal infections, and community-acquired bacterial pneumonia in adults.

Tigi 50mg Injection is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, specialized infectious disease centers, government health programs, and international pharmaceutical distributors.

Exemptia 40mg/0.8ml Injection
Composition: Adalimumab 40mg/0.8ml
International Trade Name: Exemptia®

Exemptia 40mg/0.8ml is a high-quality Adalimumab injection, a fully human monoclonal antibody equivalent to the internationally recognized product marketed under the brand name Humira®. Manufactured in WHO-GMP certified facilities, Exemptia is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs in autoimmune and inflammatory disorders.

Adalimumab is a tumor necrosis factor-alpha (TNF-α) inhibitor that helps reduce inflammation by blocking the action of TNF-α, a key mediator in the pathogenesis of autoimmune diseases. Exemptia 40mg/0.8ml Injection is primarily indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis, providing effective disease management and symptom relief.

Exemptia 40mg/0.8ml Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, specialized rheumatology and gastroenterology centers, government health programs, and international pharmaceutical distributors.

 

Fosup Kit
Composition: Aprepitant 125mg & 80mg Capsules
International Trade Name: Emend®

Fosup Kit is a high-quality Aprepitant 125mg and 80mg Capsule Kit, a Neurokinin-1 (NK1) receptor antagonist equivalent to the internationally recognized product marketed under the brand name Emend®. Manufactured in WHO-GMP certified facilities, Fosup Kit is supplied by trusted pharmaceutical exporters from India to support advanced global oncology supportive care programs.

Aprepitant selectively blocks NK1 receptors in the central nervous system, preventing the action of substance P, a key mediator of nausea and vomiting. Fosup Kit is primarily indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy, as well as moderately emetogenic chemotherapy regimens.

Fosup Kit is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The kit is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

 

Canmab 440mg Injection
Composition: Trastuzumab 440mg
International Trade Name: Herceptin®

Canmab 440mg is a high-quality Trastuzumab 440mg Injection, a biosimilar equivalent of the internationally recognized HER2-targeted monoclonal antibody marketed under the brand name Herceptin®. Manufactured in WHO-GMP certified facilities, Canmab Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast and gastric cancers.

Trastuzumab is a recombinant humanized monoclonal antibody that selectively binds to the HER2 receptor, inhibiting proliferation of HER2-overexpressing cancer cells and mediating antibody-dependent cellular cytotoxicity. This targeted mechanism allows Canmab 440mg Injection to effectively treat HER2-positive malignancies while minimizing impact on normal tissues.

Canmab 440mg Injection is primarily indicated for the treatment of HER2-positive metastatic breast cancer, early-stage breast cancer, and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, either as monotherapy or in combination with chemotherapy.

Canmab 440mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Vorizol 200mg Tablets
Composition: Voriconazole 200mg
International Trade Name: Vfend®

Vorizol 200mg is a high-quality Voriconazole 200mg tablet, a broad-spectrum triazole antifungal agent equivalent to the internationally recognized product marketed under the brand name Vfend®. Manufactured in WHO-GMP certified facilities, Vorizol is supplied by trusted pharmaceutical exporters from India to support advanced global antifungal treatment programs.

Voriconazole works by inhibiting fungal cytochrome P450-dependent enzyme 14α-sterol demethylase, disrupting ergosterol synthesis and leading to fungal cell death. Vorizol 200mg is primarily indicated for the treatment of invasive aspergillosis, candidemia in non-neutropenic patients, serious fungal infections caused by Scedosporium and Fusarium species, and other severe systemic fungal infections.

Vorizol 200mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for tertiary care hospitals, specialized infectious disease centers, government health programs, and international pharmaceutical distributors.

Cabsher 1mg Tablet
Composition: Cabergoline 1mg
International Trade Name: Dostinex®

Cabsher 1mg is a high-quality Cabergoline 1mg Tablet, a biosimilar equivalent of the internationally recognized dopamine agonist marketed under the brand name Dostinex®. Manufactured in WHO-GMP certified facilities, Cabsher is supplied by trusted pharmaceutical exporters from India to support global endocrine and reproductive health programs.

Cabergoline is a selective dopamine D2 receptor agonist that inhibits prolactin secretion from the pituitary gland. Cabsher 1mg Tablet is primarily indicated for the treatment of hyperprolactinemia, prolactin-secreting pituitary adenomas, and associated conditions such as galactorrhea, menstrual disturbances, and infertility.

Cabsher 1mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, endocrine clinics, fertility centers, government health programs, and international pharmaceutical distributors.

Celrixafor 24mg Injection
Composition: Plerixafor 24mg
International Trade Name: Mozobil®

Celrixafor 24mg is a high-quality Plerixafor 24mg Injection, a biosimilar equivalent of the internationally recognized hematopoietic stem cell mobilizer marketed under the brand name Mozobil®. Manufactured in WHO-GMP certified facilities, Celrixafor Injection is supplied by trusted pharmaceutical exporters from India to support advanced global hematology and stem cell transplantation programs.

Plerixafor is a selective CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into the peripheral blood, facilitating their collection for autologous transplantation. Celrixafor 24mg Injection is primarily indicated for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with non-Hodgkin’s lymphoma or multiple myeloma.

Celrixafor Plerixafor 24mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hematology centers, stem cell transplantation units, government health programs, and international pharmaceutical distributors.

Calcinase Nasal Spray
Composition: Calcitonin Salmon
Dosage Form: Nasal Spray
International Trade Name: Miacalcin®

Calcinase Nasal Spray is a high-quality Calcitonin Salmon formulation, a biosimilar equivalent of the internationally recognized peptide hormone marketed under the brand name Miacalcin®. Manufactured in WHO-GMP certified facilities, Calcinase Nasal Spray is supplied by trusted pharmaceutical exporters from India to support global osteoporosis and metabolic bone disorder management programs.

Calcitonin Salmon is a naturally occurring peptide hormone that inhibits osteoclastic bone resorption, helping to maintain bone density and reduce the risk of fractures. Calcinase Nasal Spray is primarily indicated for the treatment of postmenopausal osteoporosis, Paget’s disease of bone, and other conditions associated with accelerated bone loss.

Calcinase Calcitonin Salmon Nasal Spray is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The spray is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Gefticip 250mg Tablets
Composition: Gefitinib 250mg
International Trade Name: Iressa®

Gefticip 250mg is a high-quality Gefitinib 250mg Tablet, a biosimilar equivalent of the internationally recognized epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed under the brand name Iressa®. Manufactured in WHO-GMP certified facilities, Gefticip Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC).

Gefitinib is an oral targeted therapy that selectively inhibits the tyrosine kinase activity of the EGFR, blocking downstream signaling pathways involved in tumor cell proliferation and survival. This mechanism enables Gefticip 250mg Tablets to effectively control tumor growth in patients with EGFR mutation-positive NSCLC.

Gefticip 250mg Tablets are primarily indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring activating EGFR mutations, either as first-line therapy or in patients who have failed prior chemotherapy.

Gefticip 250mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Pomcad 2mg Capsule
Composition: Pomalidomide 2mg
International Trade Name: Pomalyst®

Pomcad 2mg is a high-quality Pomalidomide 2mg Capsule, a biosimilar equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Pomalyst®. Manufactured in WHO-GMP certified facilities, Pomcad is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multiple myeloma management.

Pomalidomide is an immunomodulatory agent that works by enhancing immune system activity, inhibiting angiogenesis, and directly inducing apoptosis in myeloma cells. Pomcad 2mg Capsule is primarily indicated for the treatment of multiple myeloma in patients who have received prior therapies, including lenalidomide and proteasome inhibitors, particularly in relapsed or refractory cases.

Pomcad Pomalidomide 2mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Docetere 80mg Injection
Composition: Docetaxel 80mg
International Trade Name: Taxotere®

Docetere 80mg is a high-quality Docetaxel 80mg Injection, a biosimilar equivalent of the internationally recognized taxane chemotherapeutic agent marketed under the brand name Taxotere®. Manufactured in WHO-GMP certified facilities, Docetere Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Docetaxel is a semisynthetic taxane that promotes microtubule assembly and inhibits depolymerization, thereby disrupting mitotic spindle formation and inducing apoptosis in rapidly dividing cancer cells. This mechanism allows Docetere 80mg Injection to effectively target a wide range of solid tumors, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancers.

Docetere 80mg Injection is primarily indicated for the treatment of metastatic or locally advanced solid tumors, either as monotherapy or in combination with other chemotherapeutic agents, depending on clinical protocols.

Docetere 80mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Geftib 250mg Tablets
Composition: Gefitinib 250mg
International Trade Name: Iressa

Geftib 250mg is a high-quality Gefitinib tablet, a targeted anticancer agent equivalent to the internationally recognized EGFR tyrosine kinase inhibitor therapy. Manufactured in WHO-GMP certified facilities, Geftib is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, blocking signaling pathways that promote tumor cell proliferation. Geftib 250mg Tablets are primarily indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, offering targeted therapy with improved efficacy.

Geftib 250mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Vivitra Trastuzumab Lyophilized Injection
Composition: Trastuzumab Lyophilized
International Trade Name: Herceptin® / Tresoda

Vivitra Trastuzumab Lyophilized is a high-quality Trastuzumab Lyophilized Injection, a biosimilar equivalent of the internationally recognized HER2-targeted monoclonal antibody marketed under the brand name Herceptin®. Manufactured in WHO-GMP certified facilities, Vivitra Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast and gastric cancers.

Trastuzumab is a humanized monoclonal antibody that specifically binds to the HER2 receptor, inhibiting proliferation of HER2-overexpressing cancer cells and enhancing immune-mediated cytotoxicity. Vivitra Trastuzumab Lyophilized allows for targeted therapy, improving clinical outcomes while minimizing systemic toxicity.

Vivitra Trastuzumab Lyophilized Injection is primarily indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. It is suitable for patients who are naïve to HER2-directed therapy or in combination with chemotherapy.

Vivitra Trastuzumab Lyophilized Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The lyophilized formulation is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Etovel 50mg Injection
Composition: Etoposide 50mg
International Trade Name: Posid®

Etovel 50mg is a high-quality Etoposide 50mg Injection, a therapeutic equivalent of the internationally recognized topoisomerase II inhibitor marketed under the brand name Posid®. Manufactured in WHO-GMP certified facilities, Etovel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Etoposide is a cytotoxic agent that inhibits topoisomerase II, preventing DNA unwinding and replication, leading to apoptosis in rapidly dividing cancer cells. Etovel 50mg Injection provides targeted antineoplastic activity and is widely used in the management of hematologic and solid tumors.

Etovel 50mg Injection is primarily indicated for the treatment of small cell lung cancer, testicular cancer, lymphomas, leukemias, and other malignancies where etoposide therapy is appropriate. It can be administered as monotherapy or in combination chemotherapy regimens under specialist supervision.

Etovel 50mg Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Herti 440mg Injection
Composition: Trastuzumab 440mg Injection
International Trade Name: Herceptin®

Herti 440mg is a high-quality Trastuzumab 440mg Injection, a biosimilar equivalent of the internationally recognized HER2-targeted monoclonal antibody marketed under the brand name Herceptin®. Manufactured in WHO-GMP certified facilities, Herti Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in HER2-positive breast and gastric cancers.

Trastuzumab is a humanized monoclonal antibody that binds specifically to the HER2 receptor, inhibiting the proliferation of HER2-overexpressing cancer cells and enhancing immune-mediated cytotoxicity. Herti 440mg Injection enables targeted therapy, improving clinical outcomes while minimizing systemic toxicity.

Herti 440mg Injection is primarily indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. It is particularly suitable for patients who are naïve to HER2-directed therapy or in combination with chemotherapy.

Herti 440mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Themiset Injection
Composition: Palonosetron
International Trade Name: Aloxi®

Themiset is a high-quality Palonosetron Injection, a biosimilar equivalent of the internationally recognized antiemetic marketed under the brand name Aloxi®. Manufactured in WHO-GMP certified facilities, Themiset Injection is supplied by trusted pharmaceutical exporters from India to support advanced global supportive care programs in oncology.

Palonosetron is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced nausea and vomiting (CINV) by blocking serotonin receptors in the central nervous system and gastrointestinal tract. This targeted mechanism enables Themiset Injection to provide effective prophylaxis of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.

Themiset Injection is primarily indicated for the prevention of chemotherapy-induced nausea and vomiting in adult patients undergoing cancer treatment.

Themiset Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, tertiary care hospitals, government healthcare programs, and international pharmaceutical distributors.